Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Tasly Pharmaceutical

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$98M
Portfolio companies 6
Rounds per year 0.32
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 2
Key employees Soon

Areas of investment

  • Biotechnology
  • Medical
  • Health Care
  • Pharmaceutical
  • Product Research
Summary

Tasly Pharmaceutical appeared to be the Corporate Investor, which was created in 1994. The fund was located in Asia if to be more exact in China. The main office of represented Corporate Investor is situated in the Tianjin.

The top amount of exits for fund were in 2018. Speaking about the real fund results, this Corporate Investor is 5 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Tasly Pharmaceutical performs on 16 percentage points less the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The usual things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from Tasly Pharmaceutical is 100-500 millions dollars.

The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight Ascletis, I-Mab Biopharma, Profusa. Among the most popular fund investment industries, there are Wellness, Medical Device. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Tasly Pharmaceutical, startups are often financed by C-Bridge Capital, Tianyi Group, Shenghua Group. The meaningful sponsors for the fund in investment in the same round are C-Bridge Capital, WTT Investment, VT Ventures. In the next rounds fund is usually obtained by C-Bridge Capital, WTT Investment, Tally Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Tasly Pharmaceutical:
Typical Co-investors
Tasly Pharmaceutical is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Tasly Pharmaceutical:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ADV England, London, United Kingdom
Bellwether -
Colorics International Ltd -
FoundersPad Bend, Oregon, United States
Frontline BioVentures China, Shanghai
Grupo Xango Brazil, Rio de Janeiro, Rio De Janeiro
Guangdong Songfa Ceramics Chaozhou, China, Guangdong Province
IT Farm Chiyoda, Japan
McDonnell Ventures -
MI3 Canada, Montréal, Quebec
PhillipCapital Central, Central Region, Singapore
Rowan University Glassboro, New Jersey, United States
Scania Growth Capital Södertälje, Sweden, Vasternorrlands Lan
Securian Ventures Minnesota, Saint Paul, United States
Shenlian Touzi -
Solarisbank Berlin, Berlin, Germany
Swarth Group -
Tokyo Commodity Exchange -
Xian Aerospace Base International Incubator China, Shaanxi, Xian Shi

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Zhangshang Tangyi

Health Care
Mobile Apps
Wellness
$100M07 Jan 2019 Shangcheng District, Zhejiang, China

Profusa

Biotechnology
Health Care
Medical
Medical Device
Personal Health
Wellness
$45M14 Aug 2018 San Francisco, California, United States

I-Mab Biopharma

Biotechnology
Pharmaceutical
Product Research
$220M29 Jun 2018 Shanghai, China

Shuwen Biotech

Biotechnology
Medical
11 Apr 2018 Deqing County, Zhejiang, China

I-Mab Biopharma

Biotechnology
Pharmaceutical
Product Research
$150M23 Mar 2017 China, Shanghai

Xiaoyusan

Finance
Financial Services
Insurance
Internet
Life Insurance
$15M22 Mar 2017 Futian District, Guangdong Province

Ascletis

Health Care
Medical
Therapeutics
$100M03 Jan 2017 North Carolina, United States

Ascletis

Health Care
Medical
Therapeutics
$35M02 Sep 2015 North Carolina, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Tasly Pharmaceutical?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: